Skip to main content
Top
Published in: Supportive Care in Cancer 9/2005

01-09-2005 | Original Article

Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain

Authors: Sebastiano Mercadante, Edoardo Arcuri, Flavio Fusco, Walter Tirelli, Patrizia Villari, Carlo Bussolino, Tiziana Campa, Franco De Conno, Carla Ripamonti

Published in: Supportive Care in Cancer | Issue 9/2005

Login to get access

Abstract

Tramadol is commonly used as second step drug of the analgesic ladder. In circumstances where the oral route is unavailable, rectal administration of opioids might be a simple alternative. The aim of this study was to compare the analgesic activity and tolerability of tramadol by oral and rectal administration in a double-blind, double-dummy crossover trial. The study included 60 cancer patients with cancer pain no longer responsive to non-opioid drugs. Each patient initially received oral tramadol 50 mg (drops), followed by tramadol sustained release 100 mg orally, and placebo rectally, or tramadol 100 mg rectally and placebo orally, twice a day, in a randomized sequence, on each of 3 days. Patients were allowed to take 50 mg of oral tramadol by drops as needed (four doses per day, to a maximum of 400 mg/day, including the basal dose given by the oral or rectal route). Pain intensity and relief and symptom scores were recorded every day and at the end of each phase of the crossover. The mean age of the patients was 66.1 years (SD 13.5 years); 36 were female, and 44 completed both periods. Patients dropped out due to adverse effects (15 patients) and refusal (1 patient). No differences in the use of rescue dose of oral tramadol were observed between the groups. No differences in pain intensity and relief scores, or in other symptoms between the two treatments were observed. No differences in treatment efficacy as judged by the clinician (P=0.73), in patient compliance (P=0.35), or in patient satisfaction regarding treatment (P<0.35) were found. No differences in adverse effects were found between the two treatments (25.5%, 13 patients, and 20.4%, 11 patients, with oral and rectal treatment, respectively). The proportion of preferences favored oral administration for both physicians (P=0.0002) and patients (P=0.002). Rectal administration of tramadol appears a reliable, noninvasive alternative method of pain control for patients no longer responsive to non-opioid analgesics, unable to take oral tramadol.
Literature
1.
go back to reference Babul N, Provencher L, Laberge F, Harsanyi Z, Moulin D (1998) Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 38:74–81 Babul N, Provencher L, Laberge F, Harsanyi Z, Moulin D (1998) Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 38:74–81
2.
go back to reference Bruera E, Faisinger R, Spachinsky K, Suarez-Almazor M, Inturrisi C (1995) Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 13:1520–1527 Bruera E, Faisinger R, Spachinsky K, Suarez-Almazor M, Inturrisi C (1995) Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 13:1520–1527
3.
go back to reference Cole L, Hanning C.D (1990) Review of the rectal use of opioids. J Pain Symptom Manage 5:118–126 Cole L, Hanning C.D (1990) Review of the rectal use of opioids. J Pain Symptom Manage 5:118–126
4.
go back to reference Cossmann M, Wilsmann KM (1987) Effects and side effects of tramadol. An open phase IV study with 7198 patients. Therapiewocke 37:3475–3485 Cossmann M, Wilsmann KM (1987) Effects and side effects of tramadol. An open phase IV study with 7198 patients. Therapiewocke 37:3475–3485
5.
go back to reference De Boer AG, De Leede LG, Breimer DD (1984) Drug absorption by sublingual and rectal route. Br J Anaesth 56:69–82 De Boer AG, De Leede LG, Breimer DD (1984) Drug absorption by sublingual and rectal route. Br J Anaesth 56:69–82
6.
go back to reference De Conno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E (1995) Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 13:1004–1008 De Conno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E (1995) Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 13:1004–1008
7.
go back to reference Desmeules JA (2000) The tramadol option. Eur J Pain 4 [Suppl A]:15–21 Desmeules JA (2000) The tramadol option. Eur J Pain 4 [Suppl A]:15–21
8.
go back to reference Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA (1999) High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 18:174–179CrossRefPubMed Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA (1999) High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 18:174–179CrossRefPubMed
9.
go back to reference Jadad AR, Browman GP (1995) The WHO analgesic ladder for cancer pain management. JAMA 274:1870–1873PubMed Jadad AR, Browman GP (1995) The WHO analgesic ladder for cancer pain management. JAMA 274:1870–1873PubMed
10.
go back to reference Jarlbaek L, Andersen M, Kragstrup J, Hallas J (2004) Cancer patients’ share in a population’s use of opioids. A linkage study between a prescription database and the Danish cancer registry. J Pain Symptom Manage 27:36–43CrossRef Jarlbaek L, Andersen M, Kragstrup J, Hallas J (2004) Cancer patients’ share in a population’s use of opioids. A linkage study between a prescription database and the Danish cancer registry. J Pain Symptom Manage 27:36–43CrossRef
11.
go back to reference Leow K, Smith M, Williams B, Cramond T (1992) Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52:487–495 Leow K, Smith M, Williams B, Cramond T (1992) Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52:487–495
12.
go back to reference Leow KP, Cramond T, Smith MT (1995) Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 80:296–302CrossRef Leow KP, Cramond T, Smith MT (1995) Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 80:296–302CrossRef
13.
go back to reference Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. Arzneimittelforschung 48:889–899 Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. Arzneimittelforschung 48:889–899
14.
go back to reference Lintz W, Barth H, Becker R, Frankus E, Schmidt-Bothelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. Arzneimittelforschung 48:436–445 Lintz W, Barth H, Becker R, Frankus E, Schmidt-Bothelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. Arzneimittelforschung 48:436–445
15.
go back to reference Mercadante S (1999) Treatment and outcome of cancer pain in advanced cancer patients followed at home. Cancer 85:1849–1858CrossRef Mercadante S (1999) Treatment and outcome of cancer pain in advanced cancer patients followed at home. Cancer 85:1849–1858CrossRef
16.
go back to reference Petrone D, Kamin M, Olson W (1999) Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther 24:115–123CrossRefPubMed Petrone D, Kamin M, Olson W (1999) Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther 24:115–123CrossRefPubMed
17.
go back to reference Petzke F, Radbruch L, Sabatowski R, Karthaus M, Mertens A (2001) Slow-release tramadol for treatment of chronic malignant pain—an open multicenter trial. Support Care Cancer 9:48–54 Petzke F, Radbruch L, Sabatowski R, Karthaus M, Mertens A (2001) Slow-release tramadol for treatment of chronic malignant pain—an open multicenter trial. Support Care Cancer 9:48–54
18.
go back to reference Ripamonti C, Zecca E, Brunelli C, et al (1995) Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 6:841–843 Ripamonti C, Zecca E, Brunelli C, et al (1995) Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 6:841–843
19.
go back to reference Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59:850–856PubMed Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59:850–856PubMed
20.
go back to reference Warren DE (1996) Practical use of rectal medications in palliative care. J Pain Symptom Manage 11:378–387CrossRef Warren DE (1996) Practical use of rectal medications in palliative care. J Pain Symptom Manage 11:378–387CrossRef
21.
go back to reference Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63:65–76CrossRefPubMed Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63:65–76CrossRefPubMed
Metadata
Title
Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain
Authors
Sebastiano Mercadante
Edoardo Arcuri
Flavio Fusco
Walter Tirelli
Patrizia Villari
Carlo Bussolino
Tiziana Campa
Franco De Conno
Carla Ripamonti
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0760-9

Other articles of this Issue 9/2005

Supportive Care in Cancer 9/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine